Caissa Capital Management ltd. - 04 May 2023 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
10%+ Owner
Signature
Cambyz Golestaneh, Title: Director
Issuer symbol
AVTX
Transactions as of
04 May 2023
Net transactions value
+$69,364
Form type
4
Filing time
08 May 2023, 16:10:27 UTC
Previous filing
27 Apr 2023
Next filing
16 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Purchase $41,882 +15,000 +1.1% $2.79* 1,332,700 04 May 2023 See Footnote (1) F1, F2
transaction AVTX Common Stock Purchase $14,375 +5,000 +0.38% $2.88* 1,337,700 05 May 2023 See Footnote (1) F1, F3
transaction AVTX Common Stock Purchase $13,108 +5,000 +0.37% $2.62* 1,342,700 08 May 2023 See Footnote (1) F1, F4
holding AVTX Common Stock 182,300 04 May 2023 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.58 to $2.85, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.9, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $2.68, inclusive.
F5 These shares are directly owned by Mr. Golestaneh in his personal capacity.